SAN DIEGO – At a Calbio session, Cambell Alliance, the business consulting segment of Inventiv Health Inc., presented its survey of business development professionals. Read More
Predicting protein folding has made strides in recent years, mainly through unconventional approaches. Computer games like foldit have been able to apply crowdsourcing to proteins, and solve structures that had evaded traditional computing power. Read More
For Celgene Corp., entering Japan proved a relatively brisk venture, said Jerome Zeldis, the company's chief medical officer, but China – where Celgene also has established itself, and is launching Revlimid (lenalidomide) this week – represents something more of a challenge for biotech and pharma firms. Read More
Takeda California Inc., of San Diego, a subsidiary of Takeda Pharmaceutical Co. Ltd., partnered with Sea Lane Biotechnologies, of Mountain View, Calif., giving Takeda access to Sea Lane's Concirt human antibody libraries for its drug discovery program in exchange for an up-front payment and milestone option fees for projects initiated under the collaboration. Read More
• Esperion Therapeutics Inc., of Plymouth, Mich., filed terms for its initial public offering, planning to raise $63 million by offering 4.5 million shares at a price range of $13 to $15. Read More
• Cornerstone Therapeutics Inc., of Cary, N.C., said it received on June 11 a Paragraph IV notice letter from Exela Pharma Sciences LLC, of Lenoir, N.C., advising the firm of Exela's filing of a supplemental new drug application for use of an injectable form of nicardipine hydrochloride in 9 percent sodium chloride, a generic version of Cornerstone's Cardene I.V. premixed injection. Read More
• Immunomedics Inc., of Morris Plains, N.J., said UCB SA, of Brussels, Belgium, reported new data from a Phase IIb open-label extension study of epratuzumab for systemic lupus erythematosus showing no new safety or tolerability signals, plus reduction in disease activity maintained over two years. Secondary outcome data also showed that compared to baseline values, treatment for two years with epratuzumab was associated in lower corticosteroid use. Read More
• Astrazeneca plc, of London, the University of Manchester and Cancer Research Technology, the commercial arm of Cancer Research UK, inked two agreements to seek new cancer drugs. Read More
• Janssen Research & Development LLC, of Spring House, Pa., a unit of Johnson & Johnson, said a Phase III study published in The Lancet showed patients with active psoriatic arthritis who received either Stelara (ustekinumab) 45 mg or 90 mg achieved significant improvement in joint symptoms at the study's primary endpoint, compared to patients receiving placebo. Read More